NCT02847351

Brief Summary

The study aimed to investigate whether an Arabinoxylan-enriched crackers consumption for 4 weeks in overweight and obese patients without diabetes mellitus have specific healthy effects on glycemic control (reduction of homeostatic model assessment -HOMA index-). Furthermore, study evaluated the effects of Arabinoxylan on insulin, lipid and Ghrelin.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
19

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2014

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

July 25, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 28, 2016

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

July 28, 2016

Status Verified

July 1, 2016

Enrollment Period

2 years

First QC Date

July 25, 2016

Last Update Submit

July 25, 2016

Conditions

Keywords

arabinoxylan, HOMA index, glycemic control, obesity.

Outcome Measures

Primary Outcomes (1)

  • Reduction of Homa Index after Ax Diet vs CD Diet

    The study aimed to investigate whether an Arabinoxylan enriched crackers consumption for 4 weeks in overweight or obese patients without diabetes mellitus have specific healthy effects on glycemic control, evaluated as reduction of Homa Index.

    4 weeks of arabinoxylan dietetic supplementation

Secondary Outcomes (2)

  • Improvement of lipidic profile after AxDiet vs CD Diet

    4 weeks of arabinoxylan dietetic supplementation

  • Improvement of weight after AxDiet vs CD Diet

    4 weeks of arabinoxylan dietetic supplementation

Study Arms (2)

Control Diet (CD)

PLACEBO COMPARATOR

Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.

Dietary Supplement: Arabinoxylan Diet

Arabinoxylan Diet (AXD)

EXPERIMENTAL

Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour

Dietary Supplement: Arabinoxylan Diet

Interventions

Arabinoxylan DietDIETARY_SUPPLEMENT

19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of "weight steady state". Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX). Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT).

Also known as: Integralbianco® flour- Farine Varvello
Arabinoxylan Diet (AXD)Control Diet (CD)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • males and females
  • age ≥ 18 years
  • Body mass Index ≥ 27

You may not qualify if:

  • diabetes mellitus
  • already established organ damage
  • debilitating diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IRCCS Policlinico San Matteo Foundation

Pavia, Pavia, 27100, Italy

Location

Internal Medicine Department, Clinica Medica II, IRCCS San Matteo Foundation

Pavia, PV, 27100, Italy

Location

Related Publications (1)

  • Giulia Falchi A, Grecchi I, Muggia C, Palladini G, Perlini S. Effects of a Bioavailable Arabinoxylan-enriched White Bread Flour on Postprandial Glucose Response in Normoglycemic Subjects. J Diet Suppl. 2016 Nov;13(6):626-33. doi: 10.3109/19390211.2016.1156798. Epub 2016 Apr 6.

MeSH Terms

Conditions

Nutritional and Metabolic DiseasesObesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Chiara Muggia, Medicine

    IRCCS Policlinico San Matteo Foundation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

July 25, 2016

First Posted

July 28, 2016

Study Start

July 1, 2014

Primary Completion

July 1, 2016

Study Completion

December 1, 2016

Last Updated

July 28, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share

Locations